0001193125-26-094159
SEC filingAtea Pharmaceuticals, Inc. reported a net loss of $158.3 million for fiscal year 2025, an improvement from a net loss of $193.0 million in the prior year. The company's operating expenses decreased to $180.9 million from $193.0 million, driven by reduced research and development costs. Atea remains a clinical-stage biopharmaceutical company with no commercial revenue, focusing its resources on the late-stage development of its lead HCV product candidate, the regimen of bemnifosbuvir and ruzasvir. The company's financial position is supported by $95.7 million in cash and cash equivalents and $206.1 million in marketable securities, with total assets of $315.2 million and stockholders' equity of $275.4 million as of December 31, 2025. Net cash used in operating activities was $132.0 million.
Atea Pharmaceuticals, Inc. (AVIR) reported a net loss of $158.3 million for the fiscal year ended December 31, 2025, compared to a net loss of $193.0 million in the prior year. This improvement was primarily driven by a reduction in operating expenses, which totaled $180.9 million in FY 2025, down from $193.0 million in FY 2024. The company remains a clinical-stage entity with no collaboration or product revenue. Research and development expenses were $148.0 million, while general and administrative expenses were $32.9 million. The loss from operations was $180.9 million. Other comprehensive loss was $158.4 million, which includes the net loss and an unrealized loss on investments of $59 thousand.
The company generated no revenue during the fiscal year. As stated in the document, Atea is a clinical-stage biopharmaceutical company and has not yet commercialized any products. Its operations are focused on financing, staffing, technology development, and identifying and developing product candidates. The financial resources are almost entirely devoted to research and development, including clinical trials and preclinical development activities. The absence of revenue is expected to continue until at least one product candidate successfully completes development, obtains regulatory approval, and is commercialized.
With no revenue, gross profit and gross margin metrics are not applicable. The operating loss of $180.9 million reflects the company's significant investment in its clinical programs. The primary cost drivers are research and development ($148.0 million) and general and administrative expenses ($32.9 million). The net loss of $158.3 million includes interest income and other income of $16.4 million and an income tax expense of $6.2 million. The net loss per share, basic and diluted, was $2.00, based on a weighted-average number of common shares outstanding of 81.5 million.
Net cash used in operating activities was $132.0 million for FY 2025, primarily driven by the net loss adjusted for non-cash items like stock-based compensation ($20.7 million). Net cash provided by investing activities was $188.8 million, largely from sales and maturities of marketable securities ($470.7 million) exceeding purchases ($281.9 million). Net cash used in financing activities was $25.7 million, mainly due to a $25.5 million stock repurchase program. This resulted in a net increase in cash and cash equivalents of $31.0 million for the year. The balance sheet as of December 31, 2025, shows total assets of $315.2 million, including current assets of $311.0 million (cash: $95.7M, marketable securities: $206.1M). Total liabilities are $39.8 million, resulting in stockholders' equity of $275.4 million.
The company expects to incur operating losses for the foreseeable future as it continues to advance its product candidates. Key near-term milestones include reporting topline results from the C-BEYOND HCV Phase 3 trial in mid-2026 and from the C-FORWARD trial at year-end 2026. Pending successful results, the company targets submission of a New Drug Application (NDA) to the FDA in March 2027. Atea also plans to initiate clinical development for its HEV product candidate, AT-587, with a first-in-human Phase 1 study in mid-2026. The company acknowledges significant risks, including the need for substantial additional financing, the uncertainty of clinical trial outcomes, regulatory approvals, and the ability to successfully commercialize any approved products. The financial condition and capital requirements are subject to these and other uncertainties described in the risk factors.